Submitted:
14 November 2026
Posted:
17 November 2026
You are already at the latest version
Abstract
Bacterial vaginosis (BV) is a common manifestation of vaginal dysbiosis, and recurrence after antimicrobial therapy remains frequent. This narrative review examines the rationale for restoring vaginal lactobacilli and evaluates oral and intravaginal interventions using selected clinical trials, evidence syntheses, and practice guidance. In a phase 2b trial, intravaginal Lactobacillus crispatus CTV-05 following metronidazole reduced 12-week recurrence from 45% to 30%. Trials of oral Lacticaseibacillus rhamnosus GR-1 plus Limosilactobacillus reuteri RC-14 reported inconsistent short-term cure outcomes. Meta-analyses suggest a reduction in BV recurrence with some preparations, with uncertainty arising from differences in strains, formulations, timing, and outcome definitions. Small trials of vaginal prebiotic gels report improvements in microbiological measures, while evidence for durable benefit remains limited. Available data provide insufficient support for extrapolating BV findings to vulvovaginal candidiasis, human papillomavirus clearance, or shiitake-derived adjuncts. The clearest evidence concerns specific interventions tested after standard BV treatment. Future trials should measure symptomatic recurrence alongside strain persistence and assess whether protection persists after dosing ends.
Keywords:
vaginal microbiota
; bacterial vaginosis
; recurrence
; probiotics
; live biotherapeutics
; prebiotics
Keywords.: vaginal microbiota; bacterial vaginosis; recurrence; probiotics; live biotherapeutics; prebiotics
1. Introduction
Bacterial vaginosis (BV) is a polymicrobial condition characterized by depletion of health-associated vaginal lactobacilli and enrichment of anaerobic taxa. It can present with discharge and odor, although many individuals with BV are asymptomatic. Symptomatic BV is generally treated with metronidazole or clindamycin. Recurrence is common and motivates strategies to restore a stable microbial community after treatment [1].
Vaginal dysbiosis describes a change in microbial ecology. Clinical BV requires a defined diagnostic framework, such as Amsel criteria or Nugent scoring, with validated molecular tests available in appropriate symptomatic populations. The Amsel criteria combine discharge, clue cells, vaginal pH above 4.5, and an amine odor. The Nugent score uses bacterial morphotypes on Gram staining. A change in pH or in the relative abundance of lactobacilli is an ecological outcome and has limited value as a stand-alone measure of clinical cure [1,2].
The principal question for this review is whether a specified oral or intravaginal preparation lowers the risk of recurrence after standard antimicrobial treatment. Early response during an active episode, symptom relief, and recovery of lactobacilli are considered distinct outcomes. The discussion focuses on nonpregnant adults, who account for most of the clinical evidence assessed here.
2. Review Approach
This narrative review draws on targeted searches for peer-reviewed publications indexed in PubMed, publisher records, and official clinical guidance. Searches were conducted in November 2026 using combinations of bacterial vaginosis, recurrence, probiotic, live biotherapeutic, Lactobacillus crispatus, strain identifiers, and vaginal prebiotic. Additional searches addressed candidiasis, human papillomavirus (HPV), and shiitake-derived compounds. Priority was given to randomized trials, systematic reviews, clinical guidance, and mechanistic studies directly relevant to the vaginal environment. The synthesis used selective retrieval and did not include duplicate screening, formal risk-of-bias assessment, or new statistical pooling.
3. Vaginal Ecology and Therapeutic Rationale
In reproductive-age populations, common vaginal community profiles are dominated by Lactobacillus crispatus, L. iners, L. gasseri, or L. jensenii. Some asymptomatic individuals have more diverse communities with fewer lactobacilli. A universal numerical target for vaginal lactobacilli would therefore overlook variation between individuals and across the life course [2].
Glycogen in the estrogen-responsive vaginal epithelium contributes to the pool of carbohydrates available to vaginal bacteria. Host enzymes, including alpha-amylase, can release smaller carbohydrates that some lactobacilli can use. Fermentation generates lactic acid, and vaginal fluid experiments support a direct inhibitory effect of lactic acid against several BV-associated bacteria under the conditions tested. Hydrogen peroxide production can be measured in some strains in vitro, but experiments in vaginal fluid suggest a limited antimicrobial role under physiologically relevant conditions [3,4].
Probiotic interventions depend on viable organisms delivered in an amount that confers a health benefit [5]. Candidate mechanisms include acidification, competition for epithelial adhesion sites, and inhibition of BV-associated bacteria. Mechanistic plausibility is strongest when supported by strain-resolved detection, changes in microbial function, and a clinical effect in the same trial. Even then, an association between engraftment and lower recurrence leaves open whether engraftment mediates protection or reflects a vaginal environment already favorable to recovery.
4. Clinical Evidence for Probiotic and Live Biotherapeutic Interventions
4.1. Oral Administration
Two trials of the same named oral strain pair illustrate the importance of treatment context. Anukam et al. randomized 125 participants to oral metronidazole with either L. rhamnosus GR-1 plus L. reuteri RC-14 or placebo. Among the 106 participants assessed at day 30, cure was reported in 88% of the probiotic group and 40% of the placebo group [6]. A subsequent randomized study of 126 participants in China evaluated the same pair as an adjunct to vaginal metronidazole and found no improvement in 30-day cure (57.7% vs. 59.6%) [7]. Differences in background treatment, study setting, attrition, and outcome assessment limit direct comparison. Both results concern early cure, which may diverge from longer-term recurrence.
The updated names of the oral species are Lacticaseibacillus rhamnosus and Limosilactobacillus reuteri. Lactiplantibacillus plantarum is another species used in multispecies formulations [8]. A formulation containing L. rhamnosus, L. plantarum, or Bifidobacterium animalis requires evidence for the actual strain composition, viable dose, and clinical indication. Species-level ingredient lists provide insufficient information to infer efficacy. Similarly, evidence of intestinal activity provides a rationale for investigation, while vaginal delivery or engraftment after oral administration requires direct measurement [5,6,7,8].
4.2. Intravaginal Administration
In a double-blind phase 2b trial, 228 participants who completed vaginal metronidazole were randomized to intravaginal L. crispatus CTV-05 or placebo. BV recurred by week 12 in 30% and 45%, respectively (risk ratio [RR] 0.66, 95% confidence interval [CI] 0.44–0.87). The intervention strain was detected in 79% of treated participants at week 12 and 48% at week 24. The incidence of local or systemic adverse events was similar between groups. The efficacy finding applies to the tested strain, dosing schedule, and post-antibiotic setting [9].
In a separate randomized trial, a vaginal formulation containing L. acidophilus and estriol given with oral metronidazole did not reduce six-month BV recurrence compared with oral metronidazole plus placebo [10]. A 2026 phase 1 study in the United States and South Africa reported detection of at least one administered strain in 66% of participants receiving multistrain vaginal L. crispatus live biotherapeutics. Short courses supported colonization in some participants for up to 12 weeks. The early-phase findings support further evaluation of these formulations in trials powered for clinical recurrence [11].
Table 1.
Selected trials of oral and intravaginal interventions for bacterial vaginosis.
| Study and design | Intervention and comparison | Outcome |
| Anukam et al. [6] Randomized trial, n = 125 |
Oral GR-1 + RC-14 vs. placebo, both with oral metronidazole | Day-30 cure among 106 assessed: 88% vs. 40%. |
| Zhang et al. [7] Randomized trial, n = 126 |
Oral GR-1 + RC-14 plus vaginal metronidazole vs. vaginal metronidazole alone | Day-30 cure: 57.7% vs. 59.6%. |
| Cohen et al. [9] Phase 2b trial, n = 228 |
Vaginal L. crispatus CTV-05 vs. placebo after vaginal metronidazole | Recurrence at week 12: 30% vs. 45% (RR 0.66, 95% CI 0.44–0.87). |
| Bradshaw et al. [10] Three-arm trial, n = 450 |
Vaginal L. acidophilus plus estriol vs. placebo, both with oral metronidazole | Six-month recurrence: adjusted HR 1.03 (95% CI 0.65–1.63). |
| Potloane et al. [11] Phase 1 randomized trial |
Multistrain vaginal L. crispatus formulations | At least one administered strain detected in 66% of treated participants. |
CI, confidence interval. HR, hazard ratio. RR, risk ratio. Sample sizes denote randomized participants unless otherwise specified. The Bradshaw comparison shown omits the third arm, which tested vaginal clindamycin.
4.3. Synthesis of Randomized Evidence
A 2022 meta-analysis pooled 10 randomized trials involving 1,234 participants and found a lower risk of BV recurrence with probiotics (RR 0.55, 95% CI 0.33–0.91, I2 = 45.4%) [12]. A 2026 network meta-analysis reported that short-term consolidation with vaginal probiotics had moderate-certainty evidence of benefit for early recurrence or persistence (RR 0.37, 95% CI 0.15–0.93), while oral probiotics had low-certainty evidence (RR 0.45, 95% CI 0.21–0.96) against placebo [13]. These are intervention-category estimates. The time windows, treatment sequences, and definitions of recurrence differed, and pooling cannot identify interchangeable formulations or establish superiority of one administration route. Primary trials and syntheses may overlap.
The CDC’s 2021 BV guideline found insufficient support for probiotic products as adjuncts or replacements for standard BV treatment, while separately discussing the favorable CTV-05 trial [1,9]. Later syntheses support continued investigation of defined preparations for secondary prevention [12,13]. Recurrence also has determinants outside the administered microbial community. The StepUp trial showed lower recurrence with concurrent male-partner antimicrobial treatment in the couples studied, and an ACOG clinical practice update advises consideration of concurrent partner therapy for selected patients with recurrent symptomatic BV [14,15]. Partner management can therefore influence baseline recurrence risk and merits reporting in future trials.
5. Vaginal Prebiotics and Shiitake-Derived Compounds
A prebiotic is a substrate selectively utilized by host microorganisms that confers a health benefit [16]. Glucooligosaccharides have shown selective growth effects in experiments with some vaginal lactobacilli and comparator microorganisms [17]. In a double-blind randomized study of 42 participants treated with oral metronidazole, an intravaginal glucooligosaccharide-containing gel improved short-term Nugent scores compared with placebo. In the gel group, all participants had normal scores at day 8, whereas 33% in the placebo group had intermediate or elevated scores [18]. A separate randomized trial reported favorable Amsel and Nugent findings with a prebiotic gel plus oral metronidazole [19]. These small trials leave uncertainty about durable symptomatic recurrence and the effectiveness of other delivery systems, including suppositories containing alpha-glucooligosaccharides.
Shiitake (Lentinula edodes) contains beta-glucans, including lentinan, with reported immunomodulatory activity [20]. The clinical literature on lentinan cited here concerns other indications. It does not establish vaginal exposure, strain engraftment, or prevention of BV recurrence when a shiitake-derived ingredient is added to oral bacteria or to a vaginal prebiotic. Demonstrating an incremental effect would require a defined extract and a comparator that isolates that ingredient.
6. Candidiasis and Human Papillomavirus
Vulvovaginal candidiasis is a distinct condition. A Cochrane review of nonpregnant women found possible short-term benefit from adding probiotics to antifungal treatment, based on low- or very-low-certainty evidence. Longer-term effects remained uncertain [21]. CDC guidance reports insufficient evidence for using probiotics to treat vulvovaginal candidiasis [22]. Trials in BV cannot establish efficacy against recurrent candidiasis, for which confirmation of the diagnosis and identification of the Candida species can be clinically relevant [22].
Observational studies associate certain vaginal microbial profiles with prevalent HPV infection and cervical dysplasia [23]. Such associations are susceptible to confounding and cannot establish that shifting the microbiota will accelerate viral clearance. Clinical HPV management centers on age-appropriate prevention, screening, and management of lesions [24]. Studies of HPV-related endpoints should use a virologically defined outcome and account for spontaneous clearance before attributing an effect to a microbial or mushroom-derived intervention.
7. Priorities for Clinical Research
Trials should distinguish persistence after an induction regimen from a new episode following documented resolution. A clinically interpretable primary endpoint is time to symptomatic, diagnostically confirmed recurrence after initial cure, assessed during treatment and after withdrawal. Reporting symptom resolution and antibiotic retreatment alongside pH, Nugent score, and strain-level detection would clarify the relationship between ecological changes and outcomes valued by patients.
Intervention reporting should specify the strain or strains, viable counts at administration, formulation and excipients, storage requirements, route, treatment sequence, and duration. Stratification by prior recurrence, baseline community profile, and relevant co-interventions would help identify which populations benefit. Safety reporting should record vaginal irritation, discharge, candidiasis, and discontinuations, as well as adverse events in participants at higher risk. Findings in nonpregnant adult populations have limited generalizability to pregnancy and immunocompromised populations.
For a combined oral probiotic and vaginal prebiotic regimen, a factorial trial could estimate the contribution of each component and test for interaction. A separately controlled comparison would be needed to attribute benefit to a mushroom-derived adjunct. The evidence reviewed here cannot justify the use of a fixed acute or cyclic maintenance schedule for an untested combination.
8. Conclusions
Selected microbial preparations can reduce recurrence of BV following antimicrobial therapy. The most directly interpretable evidence is for a defined intravaginal L. crispatus strain tested after metronidazole. Results for oral strain combinations are inconsistent and depend on the clinical endpoint and treatment setting. Vaginal prebiotics warrant further study for microbiological recovery and sustained symptomatic benefit. Clinical use of any formulation requires evidence that matches its composition, route, and indication.
Author Contributions
[Complete the CRediT roles for each author.]
Funding
[Insert the funding statement and grant numbers, if applicable.].
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
This review did not generate new datasets.
Conflicts of Interest
[Declare relevant financial and nonfinancial relationships, including any manufacturer involvement in the source material or manuscript.].
Use of Generative AI
ChatGPT (OpenAI, GPT-6) assisted with translation, drafting, and synthesis of published literature. [Confirm author review and responsibility before submission.].
References
- Centers for Disease Control and Prevention. Bacterial Vaginosis. STI Treatment Guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/BV.htm.
- Ravel, J.; Gajer, P.; Abdo, Z.; Schneider, G.M.; Koenig, S.S.K.; McCulle, S.L.; et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. 1), 4680–4687.. [CrossRef]
- Spear, G.T.; French, A.L.; Gilbert, D.; Zariffard, M.R.; Mirmonsef, P.; Sullivan, T.H.; et al. Human α-amylase present in lower-genital-tract mucosal fluid processes glycogen to support vaginal colonization by Lactobacillus. J. Infect. Dis. 2014, 210, 1019–1028.. [CrossRef]
- O’Hanlon, D.E.; Moench, T.R.; Cone, R.A. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect. Dis. 2011, 11, 200.. [CrossRef]
- Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506–514.. [CrossRef]
- Anukam, K.; Osazuwa, E.; Ahonkhai, I.; Ngwu, M.; Osemene, G.; Bruce, A.W.; Reid, G. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: Randomized, double-blind, placebo controlled trial. Microbes Infect. 2006, 8, 1450–1454.. [CrossRef]
- Zhang, Y.; Lyu, J.; Ge, L.; Huang, L.; Peng, Z.; Liang, Y.; Zhang, X.; Fan, S. Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an adjunctive treatment for bacterial vaginosis do not increase the cure rate in a Chinese cohort: A prospective, parallel-group, randomized, controlled study. Front. Cell. Infect. Microbiol. 2021, 11, 669901.. [CrossRef]
- Zheng, J.; Wittouck, S.; Salvetti, E.; Franz, C.M.A.P.; Harris, H.M.B.; Mattarelli, P.; et al. A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int. J. Syst. Evol. Microbiol. 2020, 70, 2782–2858.. [CrossRef]
- Cohen, C.R.; Wierzbicki, M.R.; French, A.L.; Morris, S.; Newmann, S.; Reno, H.; et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N. Engl. J. Med. 2020, 382, 1906–1915.. [CrossRef]
- Bradshaw, C.S.; Pirotta, M.; De Guingand, D.; Hocking, J.S.; Morton, A.N.; Garland, S.M.; et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: Randomised placebo-controlled double-blind trial. PLoS ONE 2012, 7, e34540.. [CrossRef]
- Potloane, D.; Symul, L.; Ngcapu, S.; Lewis, L.; France, M.; Vermeren, L.; et al. VIBRANT: A phase 1 randomized trial of multi-strain vaginal L. crispatus live biotherapeutic products in people with bacterial vaginosis. Cell Host Microbe 2026, 34, 751–760.e5.. [CrossRef]
- Chieng, W.K.; Abdul Jalal, M.I.; Bedi, J.S.; Zainuddin, A.A.; Mokhtar, M.H.; Abu, M.A.; Chew, K.T.; Nur Azurah, A.G. Probiotics, a promising therapy to reduce the recurrence of bacterial vaginosis in women? A systematic review and meta-analysis of randomized controlled trials. Front. Nutr. 2022, 9, 938838.. [CrossRef]
- Gardella, B.; Dominoni, M.; Pano, M.R.; Lovotti, A.; Spinillo, A. Rethinking prevention of recurrent bacterial vaginosis: A comparative effectiveness network meta-analysis. J. Low. Genit. Tract Dis. 2026, 30, 325–340.. [CrossRef]
- Vodstrcil, L.A.; Plummer, E.L.; Fairley, C.K.; Hocking, J.S.; Law, M.G.; Petoumenos, K.; et al. Male-partner treatment to prevent recurrence of bacterial vaginosis. N. Engl. J. Med. 2025, 392, 947–957.. [CrossRef]
- American College of Obstetricians and Gynecologists. Concurrent sexual partner therapy to prevent bacterial vaginosis recurrence. Obstet. Gynecol. 2025, 146, e111–e114.. [CrossRef]
- Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 491–502.. [CrossRef]
- Rousseau, V.; Lepargneur, J.P.; Roques, C.; Remaud-Siméon, M.; Paul, F. Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms. Anaerobe 2005, 11, 145–153.. [CrossRef]
- Coste, I.; Judlin, P.; Lepargneur, J.P.; Bou-Antoun, S. Safety and efficacy of an intravaginal prebiotic gel in the prevention of recurrent bacterial vaginosis: A randomized double-blind study. Obstet. Gynecol. Int. 2012, 2012, 147867.. [CrossRef]
- Hakimi, S.; Farhan, F.; Farshbaf-Khalili, A.; Dehghan, P.; Javadzadeh, Y.; Abbasalizadeh, S.; Khalvati, B. The effect of prebiotic vaginal gel with adjuvant oral metronidazole tablets on treatment and recurrence of bacterial vaginosis: A triple-blind randomized controlled study. Arch. Gynecol. Obstet. 2018, 297, 109–116.. [CrossRef]
- Zhang, M.; Zhang, Y.; Zhang, L.; Tian, Q. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Prog. Mol. Biol. Transl. Sci. 2019, 163, 297–328.. [CrossRef]
- Xie, H.Y.; Feng, D.; Wei, D.M.; Mei, L.; Chen, H.; Wang, X.; Fang, F. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst. Rev. 2017, 11, CD010496.. [CrossRef]
- Centers for Disease Control and Prevention. Vulvovaginal Candidiasis. STI Treatment Guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm.
- Norenhag, J.; Du, J.; Olovsson, M.; Verstraelen, H.; Engstrand, L.; Brusselaers, N. The vaginal microbiota, human papillomavirus and cervical dysplasia: A systematic review and network meta-analysis. BJOG 2020, 127, 171–180.. [CrossRef]
- Centers for Disease Control and Prevention. Human Papillomavirus (HPV) Infection. STI Treatment Guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/hpv.htm.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.